



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO-IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

A. JANARDHAN RAO¹, V. KOTESWARA RAO¹, P. VISWESWARA RAO²,
B. SATHEESH KRISHNA¹, C. NAGA RAJU^{*1} AND S. K. GHOSH³

¹Department of Chemistry, Sri Venkateswara University, Tirupati – 517 502, India

²Department of Biotechnology, Sri Venkateswara University, Tirupati – 517 502, India

³Bioorganic Division, Bhabha Atomic Research Centre, Mumbai-400 085, India.

*Corresponding author naga_raj04@yahoo.co.in

ABSTRACT

Synthesis of a series of novel iminophosphorane derivatives of Zidovudine (AZT) was accomplished through Staudinger reaction. In the first step PBr_3 was reacted with various substituted phenolic and amino compounds in the presence of triethylamine (TEA) in dry tetrahydrofuran (THF) under nitrogen atmosphere followed by cyclisation of (\pm) 2-aminomethyl piperidine, afforded diazaphosphole P(III) intermediates (**3a-l**). They were further reacted with zidovudine to obtain iminophosphorane derivatives **4a-l**. They showed promising antioxidant activity. Their antioxidant activity was greatly influenced by the presence of different bio-active groups at phosphorus.

KEYWORDS

Diazaphospholo-imine derivatives of AZT, Staudinger Reaction, Antioxidant activity, Iminophosphoranes.

INTRODUCTION

The Staudinger reaction¹⁻³ reaction of tertiary phosphines with organic azides forms iminophosphoranes. In a few reactions phosphazides, the primary imination products have been isolated.⁴⁻⁶ In some cases iminophosphoranes are trapped via an intramolecular reaction⁷ almost in practically quantitative yields. Iminophosphoranes have wide range of applications, such as modification of cell surfaces, protein engineering, specific labeling of nucleic acids, proteomic studies and as a general tool for bioconjugation.⁸ Substituted 2-(aminomethyl) piperidines are a novel class of selective protein kinase C⁹ which has emerged as a pivotal mediator in

cellular regulation, signal transduction and neoplastic promotion. In general, the biological activity of nucleosides is dependent on their ability to be converted intracellularly to the corresponding mono-, di- and tri phosphates by cellular kinases.¹⁰ Some of them are an important class of antiviral and anticancer therapeutics. Nucleoside amino acid phosphoramidate monoesters have been shown to play a potential pronucleotide strategy.¹¹ In particular, AZT-amino acid phosphoramidates are potent nontoxic antiviral and anticancer agents.¹²⁻¹⁶ A major limitation for AZT for the treatment of AIDS is the occurrence of side effect, such as leucopenia. Oxidative stress is involved in AZT-induced leukopenia which may be prevented by treatment with antioxidants.¹⁷ Further



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

the relationship between cancer and antioxidants is also a significant factor since there is a battle between cancer and antioxidants. Cancer works against the cells in the body while antioxidants work on behalf of cells.

In view of this back ground, we synthesized iminophosphoranes of zidovudine through Staudinger reaction by incorporating the bioactive groups at the phosphorus atom. They are expected to have better antioxidant activities. The effect of iminophosphoranes of zidovudine on the oxidative stress was evaluated by DPPH, Nitric oxide Scavenging methods. The structures of all the synthesized compounds were established by elemental analyses ,IR, ^1H , ^{13}C , ^{31}P NMR and mass spectral data.

MATERIALS AND METHODS


Chemicals were procured from Sigma-Aldrich, Merck and Lancaster, and were used as such without further purification. All solvents used for spectroscopic and other physical studies were reagent grade and were further purified by literature methods.¹⁸ Melting points were determined using a calibrated thermometer by Guna Digital Melting Point apparatus. They are expressed in degrees centigrade . IR spectra were obtained on a Perkin-Elmer Model 281-B spectrophotometer in KBr disks and absorptions were reported in cm^{-1} . ^1H and ^{13}C NMR spectra were recorded as solutions in CDCl_3 on a Bruker AVANCE III 500 MHz spectrometer operating at 500 MHz for ^1H , 125 MHz for ^{13}C and 202.4 MHz for ^{31}P NMR. The ^1H , ^{13}C and ^{31}P chemical shifts were expressed in ppm with reference to tetramethylsilane and 85 % H_3PO_4 respectively.

Mass spectra were recorded on a JEOL GCMATE II Mass spectrometer. Elemental analyses were performed by Central Drug Research Institute, Lucknow, INDIA.

General Procedure for the Preparation of (4a-l)

A solution of various phenols and amino acid esters (0.002 mole), in dry THF (10 mL) and triethylamine (0.002 mole), was added dropwise over a period of 15 minutes to a stirred solution of phosphorustribromide (0.002 mole) in 10 mL of THF at $-15-0^\circ\text{C}$ under nitrogen atmosphere. After stirring for 3 hours at 0°C , formation of intermediate dibromides **2a-l** was ascertained by TLC run in 7:3 mixture of ethyl acetate and hexane. To this (\pm) 2-amino methyl piperidine (0.002 mole) and triethylamine (0.004 mole), in 10 mL of THF were added dropwise at 0°C . After completion of the addition, the temperature was slowly raised to RT. The completion of the reaction (3 h) was ascertained by TLC run in 7:3 mixture of ethylacetate and hexane. The reaction mixture was filtered to remove triethylamine hydrobromide. The filtrate containing diazaphospholes (**3a-l**) was taken into a reaction flask under nitrogen atmosphere to which AZT (0.002 mole) in THF (10 mL) was added at RT and slowly raised the temperature to reflux and continued stirring for 2-3 h. The progress of the reaction was monitored by TLC. Solvent was removed in a rotaevaporator and the crude product was purified by column chromatography on silica gel (60-120 mesh) with ethyl acetate: hexane (4:6) as eluent to afford pure iminophosphoranes **4a-l**. All the title compounds were characterized by IR, ^1H , ^{13}C , ^{31}P NMR and mass spectral analyses.

SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION



Compound	R	Compound	R	Compound	R
4a		4e		4i	
4b		4f		4j	
4c		4g		4k	
4d		4h		4l	

Scheme-1. Synthesis of 4a-l

1-(5-(hydroxymethyl)-4-[[1-(4-nitrophenoxy)perhydro-1λ⁵-[1,3,2]diazaphospholo[1,5a]pyridine-1-ylidene]amino]tetrahydro-2-furyl)-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedione (**4a**): Yield: 65%. M.p: 128-130 °C. Anal. Calcd. for C₂₂H₂₉N₆O₇P: C, 50.77; H, 5.62; N, 16.15. Found C, 50.67; H, 5.59; N, 16.21. IR (KBr): 3496 (-OH), 3369 (-NH), 1731 (C=O), 1258 (P=N), 1213, 948 (P-O-C_{aryl}) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 9.51 (s, 1H, NH), 8.12 (d, 2H, *J* = 9.5 Hz, Ar-H), 7.53 (d, 2H, *J* = 9 Hz, Ar-H), 7.40 (d, 1H, *J* = 1.5 Hz, CH=C), 6.18 (t, 1H, *J* = 13.5 Hz, N-CH-O), 5.35 (br, 1H, P-NH), 4.30-4.34 (m, 1H, CH₂-OH), 4.05-4.1 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.65-3.68 (m, 1H, P=N-CH), 2.65-2.71 (m, 2H, NH-CH₂), 2.40-2.49 (m, 3H, P-N-CH₂, P-N-CH), 2.23-2.37 (m, 2H, P=N-CH-CH₂), 1.95 (s, 3H, CH₃), 1.27-1.34 (m, 6H, CH₂-CH₂-CH₂). ¹³C-NMR (125 MHz, CDCl₃): δ 163.7 (C-4'), 155.5 (Ar-C-1), 150.2 (C-2'), 139.5 (Ar-C-4), 135.6 (C-6'), 125.8 (Ar-C-3, Ar-C-5), 121.5 (Ar-C-2, Ar-C-6), 111.5 (C-5'), 85.0 (C-4''), 82.0 (C-1''), 62.2 (C-5''), 58.9 (C-7a), 37.2 (C-4), 32.7 (C-8), 31.8 (C-2''), 29.6 (C-3''), 29.5 (C-7), 29.3 (C-5), 22.6 (C-6), 12.5 (-CH₃). ³¹P-NMR (202 MHz, CDCl₃): δ 7.83. GCMS (*m/z*; %): (521.31, 45%) [MH]⁺.



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

1-[4-[[1-(4-bromophenoxy)perhydro-1 λ^5 -[1,3,2]diazaphospholo[1,5-a]pyridin-1-yliden]amino]-5-(hydroxymethyl)tetrahydro-2-furanyl]-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedione (**4b**): Yield: 59%. M.p: 135-137 °C. Anal. Calcd. for C₂₂H₂₉BrN₅O₅P: C, 47.66; H, 5.27; N, 12.63. Found C, 47.59; H, 5.18; N, 12.77. IR (KBr): 3487 (-OH), 3355 (-NH), 1729 (C=O), 1254 (P=N), 1215, 947 (P-O-C_{aryl}) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 9.32 (s, 1H, NH), 7.47 (d, 2H, *J* = 9.5 Hz, Ar-H); 7.44 (d, 2H, *J* = 9.2 Hz, Ar-H), 7.36 (d, 1H, *J* = 1.3 Hz, CH=C), 6.17 (t, 1H, *J* = 12.5 Hz, N-CH-O), 5.32 (br, 1H, P-NH), 4.32-4.36 (m, 1H, CH₂-OH), 3.94-3.99 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.62-3.65 (m, 1H, P=N-CH), 2.64-2.72 (m, 2H, NH-CH₂), 2.43-2.53 (m, 3H, P-N-CH₂, P-N-CH), 2.02-2.1 (m, 2H, P=N-CH-CH₂), 1.91 (s, 3H, CH₃), 1.25-1.35 (m, 6H, CH₂-CH₂-CH₂). ¹³C-NMR (125 MHz, CDCl₃): δ 163.5 (C-4'), 152.1 (Ar-C-1), 150.9 (C-2'), 136.8 (C-6'), 134.2 (Ar-C-3, Ar-C-5), 123.5 (Ar-C-2, Ar-C-6), 117.5 (Ar-C-4), 110.5 (C-5'), 84.9 (C-4''), 82.9 (C-1'''), 61.0 (C-5'''), 56.9 (C-7a), 36.9 (C-4), 32.9 (C-8), 31.7 (C-2''), 29.6 (C-3''), 29.6 (C-7), 29.3 (C-5), 22.9 (C-6), 13.1 (-CH₃). ³¹P-NMR (202 MHz, CDCl₃): δ 10.4. GCMS (*m/z*; %): (555.30, 30%) [MH]⁺.

1-[4-[[1-(4-chlorophenoxy)perhydro-1 λ^5 -[1,3,2]diazaphospholo[1,5-a]pyridin-1-yliden]amino]-5-(hydroxymethyl)tetrahydro-2-furanyl]-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedione (**4c**): Yield 61%. M.p: 127-29 °C. Anal. Calcd. for C₂₂H₂₉ClN₅O₅P: C, 51.82; H, 5.73; N, 13.73. Found C, 51.88; H, 5.79; N, 13.65. IR (KBr): 3491 (-OH), 3364 (-NH), 1730 (C=O), 1262 (P=N), 1213, 948 (P-O-C_{aryl}) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 8.97 (s, 1H, NH), 7.46 (d, 1H, *J* = 1.5 Hz, CH=C), 7.37 (d, 2H, *J* = 9.0 Hz, Ar-H); 7.21 (d, 2H, *J* = 8.5 Hz, Ar-H), 6.12 (t, 1H, *J* = 13.5 Hz, N-CH-O), 5.34 (br, 1H, P-NH), 4.29-4.34 (m, 1H, CH₂-OH), 4.01-4.06 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.68-3.77 (m, 1H, P=N-CH), 2.63-2.68 (m, 2H, NH-CH₂), 2.38-2.48 (m, 3H, P-N-CH₂, P-N-CH), 2.01-2.09 (m, 2H, P=N-CH-CH₂), 1.92 (s, 3H, CH₃), 1.23-1.31 (m, 6H, CH₂-CH₂-CH₂). ¹³C-NMR (125 MHz, CDCl₃): δ 163.6 (C-4'), 155.3 (Ar-C-1), 150.6 (C-2'), 126.1 (Ar-C-3, Ar-C-5), 122.2 (Ar-C-2, Ar-C-6), 140.5 (Ar-C-4), 136.2 (C-6'), 111.7 (C-5'), 84.9 (C-4''), 83.1 (C-1'''), 61.9 (C-5'''), 59.2 (C-7a), 37.8 (C-4), 32.8 (C-8), 31.9 (C-2''), 29.3 (C-3''), 29.5 (C-7), 28.5 (C-5), 22.54 (C-6), 12.4 (-CH₃), ³¹P-NMR (202 MHz, CDCl₃): δ 6.9. GCMS (*m/z*; %): (510.23, 30%) [MH]⁺.

1-[4-[[1-(2,4-dichlorophenoxy)perhydro-1 λ^5 -[1,3,2]diazaphospholo[1,5-a]pyridin-1-yliden]amino]-5-(hydroxymethyl)tetrahydro-2-furanyl]-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidine-dione (**4d**): Yield 58%. M.p: 132-135 °C. Anal. Calcd. for C₂₂H₂₈Cl₂N₅O₅P: C, 48.54; H, 5.18; N, 12.87. Found C, 48.62; H, 5.21; N, 12.76. IR (KBr): 3489 (-OH), 3359 (-NH), 1729 (C=O), 1264 (P=N), 1218, 950 (P-O-C_{aryl}) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 9.52 (s, 1H, NH); 7.62 (s, 1H, Ar-H); 7.33 (d, 1H, *J* = 9.5 Hz, Ar-H), 7.29 (d, 1H, *J* = 1.6 Hz, CH=C), 7.09 (d, 1H, *J* = 9.0 Hz, Ar-H), 6.14 (t, 1H, *J* = 12.5 Hz, N-CH-O), 5.31 (br, 1H, P-NH), 4.30-4.34 (m, 1H, CH₂-OH), 4.07-4.12 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.7-3.79 (m, 1H, P=N-CH), 2.63-2.71 (m, 2H, NH-CH₂), 2.42-2.5 (m, 3H, P-N-CH₂, P-N-CH), 2.01-2.08 (m, 1H, P=N-CH-CH₂), 1.93 (s, 3H, CH₃), 1.26-1.36 (m, 6H, CH₂-CH₂-CH₂). ³¹P-NMR (202 MHz, CDCl₃): δ 12.1. GCMS (*m/z*; %): (545.25, 40%) [MH]⁺.



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

1-(5-(hydroxymethyl)-4-{{1-(3-pyridyloxy)perhydro-1 λ^5 -[1,3,2] diazaphospholo[1,5-a] pyridine-1-yliden} amino} tetra hydro-2- furyl)-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedione (**4e**): Yield 61%. M.p: 141 $^\circ$ -143C. IR (KBr): 3492 (-OH), 3365 (-NH), 1725 (C=O), 1258 (P=N), 1210, 953 (P-O-C_{aryl}) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 9.63 (s, H, NH), 7.87-7.98 (m, 4H, Ar-H), 7.35 (d, 1H, $J = 1.4$ Hz, CH=C), 6.11 (t, 1H, $J = 13.5$ Hz, N-CH-O), 5.33 (br, 1H, P-NH), 4.31-4.35 (m, 1H, CH₂-OH), 4.04-4.1 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.69-3.77 (m, 1H, P=N-CH), 2.65-2.71 (m, 2H, NH-CH₂), 2.39-2.49 (m, 3H, P-N-CH₂, P-N-CH), 2.01-2.09 (m, 1H, P=N-CH-CH₂), 1.92 (s, 3H, CH₃), 1.23-1.31 (m, 6H, CH₂-CH₂-CH₂). ³¹P-NMR (202 MHz, CDCl₃): δ 7.8.

1-[5-(hydroxymethyl)-4-({1-(3-pyridylmethyl)amino}perhydro-1 λ^5 [1,3,2]diazaphospholo[1,5-a] pyridine-1-yliden} amino)tetra hydro-2- furyl]-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedione. (**4f**): Yield 63%. M.p: 153-155 $^\circ$ C. IR (KBr): 3497 (-OH), 3369 (-NH), 1725 (C=O), 1248 (P=N) cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 9.68 (s, H, NH), 7.91-8.03 (m, 4H, Ar-H), 7.38 (d, 1H, $J = 1.5$ Hz, CH=C), 6.09 (t, 1H, $J = 13.0$ Hz, N-CH-O), 5.32 (br, 1H, P-NH), 4.28-4.33 (m, 1H, CH₂-OH), 4.15-4.21 (m, 3H, Py-CH₂-NH, Py-CH₂-NH), 3.97-4.03 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.67-3.75 (m, 1H, P=N-CH), 2.64-2.7 (m, 2H, NH-CH₂), 2.37-2.46 (m, 3H, P-N-CH₂, P-N-CH), 2-2.09 (m, 1H, P=N-CH-CH₂), 1.9 (s, 3H, CH₃), 1.23-1.31 (m, 6H, CH₂-CH₂-CH₂). ³¹P-NMR (202 MHz, CDCl₃): δ 11.4.

1-[5-(hydroxymethyl)-4-({1-(2-Thienylmethyl)amino}perhydro-1 λ^5 [1,3,2]diazaphospholo[1,5-a] pyridine-1-yliden} amino)tetrahydro-2- furyl]-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedione. (**4g**): Yield 64%. M.p: 141-143 $^\circ$ C. Anal. Calcd. for C₂₁H₃₁N₆O₄PS: C, 51.00; H, 6.32; N, 16.99. Found C, 51.15; H, 6.39; N, 16.75. IR (KBr): 3490 (-OH), 3362 (-NH), 1730 (C=O), 1245 (P=N) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 9.7 (s, H, NH), 7.47 (d, 1H, $J = 1.4$ Hz, CH=C), 7.37-7.40 (3H, Thio-H), 6.10 (t, 1H, $J = 13$ Hz, N-CH-O), 5.31 (br, 1H, P-NH), 4.39-4.43 (m, 1H, CH₂-OH), 4.12-4.19 (m, 3H, Thio-CH₂-NH, Thio-CH₂-NH), 4-3.95 (m, 3H, CH₂-OH, CH-CH₂-OH), 3.81-3.83 (m, 1H, P=N-CH), 2.49-2.55 (m, 2H, NH-CH₂), 2.38-2.43 (m, 3H, CH₂-N-P, CH-N-P), 2.01-2.09 (m, 1H, P=N-CH-CH₂), 1.24-1.34 (m, 6H, CH₂-CH₂-CH₂), 1.90 (s, 3H, CH₃), 1.24-1.34 (m, 6H, CH₂-CH₂-CH₂). ¹³C-NMR (125 MHz, CDCl₃): δ 163.71 (C-4'), 150.28 (C-2'), 139.51 (Thio-C-2), 136.81 (C-6'), 125.9 (Thio-C-3), 126.4 (Thio-C-4), 124.1 (Thio-C-5), 111.25 (C-5'), 86.67 (C-4''), 84.54 (C-1'), 61.95 (C-5''), 59.99 (C-7a), 37.31 (C-4), 33.81 (C-8), 31.92 (C-2''), 31.42 (Thio-CH₂), 29.69 (C-3''), 29.65 (C-7), 29.61 (C-5), 22.68 (C-6), 12.4 (CH₃). ³¹P-NMR (202 MHz, CDCl₃): δ 10.9. GCMS (m/z ; %): (495.25, 38%) [MH]⁺.

1-[4-({1-(2-furylmethyl)amino}perhydro-1 λ^5 -[1,3,2]diazaphospholo[1,5-a]pyridin-1-yliden} amino)-5-(hydroxymethyl)tetrahydro-2-furyl]-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidine-dione(**4h**): Yield 59%. M.p: 138-141 $^\circ$ C. IR (KBr): 3489 (-OH), 3365 (-NH), 1731 (C=O), 1247 (P=N). ¹H-NMR (500 MHz, CDCl₃): δ 9.68 (s, H, NH), 7.45 (d, 1H, $J = 1.6$ Hz, CH=C), 7.39-7.43 (3H, Fu-H), 6.09 (t, 1H, $J = 12.5$ Hz, N-CH-O), 5.29 (br, 1H, P-NH), 4.45-4.49 (m, 1H, CH₂-OH), 4.03-3.98 (m, 3H, CH-CH₂-OH, CH₂-OH), 4.1-4.16 (m, 3H, Fu-CH₂-NH, Fu-CH₂-NH), 3.85-3.88 (m, 1H, P=N-CH), 2.36-2.41 (m, 2H, NH-CH₂), 2.25-2.35 (m, 3H, CH₂-N-P, CH-N-P), 2.05-2.12 (m, 1H, P=N-CH-CH₂), 1.87 (s, 3H, CH₃), 1.23-1.34 (m, 6H, CH₂-CH₂-CH₂). ³¹P-NMR (202 MHz, CDCl₃): δ 11.7.



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

1-[5-(hydroxymethyl)-4-({1-(1-phenylethyl)amino}perhydro-1 λ 5[1,3,2]diazaphospholo[1,5-a]pyridine-1-ylidene)amino)tetrahydro-2-furyl]-5-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedione (**4i**): Yield 63%. M.p: 144-146 °C. IR (KBr): 3487 (-OH), 3359 (-NH), 1721 (C=O), 1265 (P=N) cm^{-1} . $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 9.12 (br, H, NH), 7.37 (d, 1H, $J = 1.4$ Hz, CH=C), 7.02-7.32 (m, 5H, Ar-H), 6.11 (t, 1H, $J = 13.5$ Hz, N-CH-O), 5.28 (s, 1H, P-NH), 4.45-4.52 (m, 2H, Ar-CH-NH, Ar-CH-NH), 4.34-4.38 (m, 1H, CH₂-OH), 4.03-3.97 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.72-3.67 (m, 1H, P=N-CH), 2.54-2.60 (m, 2H, NH-CH₂), 2.34-2.44 (m, 3H, CH₂-N-P, CH-N-P), 2.04-2.1 (m, 1H, P=N-CH-CH₂), 1.95 (s, 3H, CH₃), 1.64-1.66 (d, 3H, CH₃-CH-Ar), 1.24-1.34 (m, 6H, CH₂-CH₂-CH₂). $^{31}\text{P-NMR}$ (202 MHz, CDCl_3): δ 12.31. GCMS (m/z ; %): (503.79, 20%) $[\text{MH}]^+$.

Ethyl2-[(1-{[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1-pyrimidinyl)tetrahydro-3-furanyl]imino}perhydro-1 λ 5-[1,3,2]diazaphospholo[1,5-a]pyridin-1-yl)amino]-2-phenyl- acetate (**4j**): Yield 51%. M.p: 147-149 °C. Anal. Calcd. for $\text{C}_{26}\text{H}_{37}\text{N}_6\text{O}_6\text{P}$: C, 55.71; H, 6.65; N, 14.99. Found C, 55.68; H, 6.61; N, 15.07. IR (KBr): 3494 (-OH), 3366 (-NH), 1723 (C=O), 1258 (P=N) cm^{-1} . $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 8.72 (s, H, NH), 7.51-7.60 (5H, Ar-H), 7.40 (d, 1H, $J = 1.5$ Hz, CH=C), 6.07 (t, 1H, $J = 13.0$ Hz, N-CH-O), 5.35 (br, 1H, P-NH), 4.93- 5.01 (m, 2H, Ph-CH, Gly-NH), 4.41-4.45 (m, 1H, CH₂-OH), 3.98-4.03 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.82-3.85 (m, 1H, P=N-CH), 3.72 (q, 2H, O-CH₂-CH₃), 2.54-2.60 (m, 2H, NH-CH₂), 2.34-2.44 (m, 3H, CH₂-N-P, CH-N-P), 2.01-2.09 (m, 1H, P=N-CH-CH₂), 1.94 (s, 3H, CH₃), 1.25-1.35 (m, 6H, CH₂-CH₂-CH₂), 1.12 (t, 3H, $J = 6.5$ Hz, -CH₃). $^{13}\text{C-NMR}$ (125 MHz, CDCl_3): δ 174.2 (Gly-CO), 163.7 (C-4'), 155.5 (Ar-C-1), 150.2 (C-2'), 125.8 (Ar-C-3, Ar-C-5), 121.5 (Ar-C-2, Ar-C-6), 139.5 (Ar-C-4), 135.8 (C-6'), 111.5 (C-5'), 85.0 (C-4''), 82.0 (C-1''), 62.2 (C-5''), 58.9 (C-7a), 37.2 (C-4), 32.7 (C-8), 31.8 (C-2''), 29.6 (C-3''), 29.5 (C-7), 29.5 (C-5), 22.6 (C-6), 12.5 (-CH₃). $^{31}\text{P-NMR}$ (202 MHz, CDCl_3): δ 12.9. GCMS (m/z ; %): (561.45, 30%) $[\text{MH}]^+$.

Ethyl2-amino-3-[(1-{[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1-pyrimidinyl)tetrahydro-3-furanyl]imino}perhydro-1 λ 5-[1,3,2]diazaphospholo[1,5-a]pyridin-1-yl)sulfanyl]propanoate (**4k**): Yield 57%. M.p: 131-133 °C. IR (KBr): 3488 (-OH), 3359 (-NH), 1725 (C=O), 1258 (P=N) cm^{-1} . $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 9.61 (s, 1H, NH), 7.38 (d, 1H, $J = 1.6$ Hz, CH=C), 6.06-6.09 (t, 1H, $J = 12.5$ Hz, N-CH-O), 5.31 (br, 1H, P-NH), 4.52-4.54 (m, 2H, -NH₂), 4.39-4.44 (m, 1H, CH₂-OH), 4.05-3.99 (m, 3H, CH-CH₂-OH, CH₂-OH), 3.83-3.79 (m, 2H, P=N-CH, CH-NH₂), 3.69 (q, 2H, -O-CH₂-CH₃), 2.95-2.83 (m, 2H, S-CH₂), 2.52-2.58 (m, 2H, NH-CH₂), 2.4-2.49 (m, 3H, CH₂-N-P, CH-N-P), 1.99-2.06 (m, 1H, P=N-CH-CH₂), 1.89 (s, 3H, CH₃), 1.22-1.33 (m, 6H, CH₂-CH₂-CH₂), 1.15 (t, 3H, O-CH₂-CH₃). $^{31}\text{P-NMR}$ (202 MHz, CDCl_3): δ 9.7.

Methyl2-[(1-{[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydro-1-pyrimidinyl)tetrahydro-3-furanyl]imino}perhydro-1 λ 5-[1,3,2]diazaphospholo[1,5-a]pyridin-1-yl)amino]-3-methylbutanoate (**4l**): Yield 61%. M.p: 126-128 °C. IR (KBr): 3491 (-OH), 3365 (-NH), 1724 (C=O), 1252 (P=N) cm^{-1} . $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 9.59 (s, H, NH), 7.35 (d, 1H, $J = 1.4$ Hz, CH=C), 6.13 (t, 1H, $J = 13.0$ Hz, N-CH-O), 5.26 (br, 1H, P-NH), 4.34-4.38 (m, 1H, CH₂-OH), 4.2-4.26 (m, 1H, Val-NH, Val-NH-CH), 4.03-3.97 (m, 3H, CH-CH₂-OH,



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

$\text{CH}_2\text{-OH}$), 3.85 (s, 3H, O- CH_3), 3.72-3.76 (m, 1H, P=N- CH), 2.54-2.60 (m, 2H, NH- CH_2), 2.34-2.44 (m, 3H, $\text{CH}_2\text{-N-P}$, CH-N-P), 2.04-2.1 (m, 1H, P=N- CH-CH_2), 1.94 (s, 3H, CH_3), 1.52-1.46 (m, 1H, - $\text{CH}(\text{CH}_3)_2$), 1.25-1.35 (m, 6H, $\text{CH}_2\text{-CH}_2\text{-CH}_2$), 1.13 (d, 6H, $J = 6.5 \text{ Hz}$, - $\text{CH}(\text{CH}_3)_2$). $^{31}\text{P-NMR}$ (202 MHz, CDCl_3): δ 4.4. GCMS (m/z ; %): (513.1, 58%) $[\text{MH}]^+$.

ANTIOXIDANT ACTIVITY

The antioxidant activity of the iminophosphorane derivatives of Zidovudine (**3a-l**) has been evaluated and their results are presented in Table 1. The antioxidant activity was evaluated by DPPH,¹⁹ Nitric oxide Scavenging methods.²⁰ Vitamin C is used as a standard for antioxidant activity.

Table .1

Antioxidant activity of Iminophosphorane derivatives of Zidovudine (4a-l).

Compounds	%DPPH Scavenging activity ($\mu\text{g/mL}$)	Nitric oxide scavenging Activity (%)
4a	74.45 \pm 2.31	65.36 \pm 0.72
4b	80.43 \pm 1.94	74.15 \pm 3.53
4c	78.67 \pm 1.23	67.54 \pm 0.21
4d	77.56 \pm 1.62	71.56 \pm 2.27
4e	73.21 \pm 1.64	69.32 \pm 1.62
4f	78.82 \pm 1.26	65.41 \pm 0.55
4g	79.23 \pm 3.01	72.11 \pm 2.18
4h	77.76 \pm 1.81	70.54 \pm 1.98
4i	79.19 \pm 2.43	72.19 \pm 2.22
4j	81.61 \pm 1.25	76.43 \pm 1.54
4k	79.73 \pm 2.12	73.73 \pm 2.12
4l	78.43 \pm 2.89	72.38 \pm 1.09



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO-IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

AZT	70.34 ± 1.32	67.27 ± 1.36
Vitamin C	82.30 ± 1.66	79.65 ± 1.23

DPPH free radical-scavenging assay

The antiradical activity of iminophosphoranes of AZT (**4a-l**) were measured in triplicate using a modified Yamaguchi *et al.* method. A methanolic solution of DPPH (4 mL, 40 ppm) was added to 1 mL of the antioxidant solutions in 0.1 M Tris-HCl buffer (pH 7.1) at 25 °C, giving final concentrations of 10, 25, 50 and 100 µM. The absorbance read at 517 nm was measured after 60 min of the reaction in the dark and compared with the control prepared in a similar way without the addition of the test compounds. A 100 µM solution of Vitamin C (a strong and natural antioxidant agent) was also tested as a control for the reaction. In this case, the violet color of DPPH disappeared immediately. We confirmed that the test compounds (**4a-l**) showed significant antioxidant activity when compared to the parent drug and Vitamin C.

$$\text{Antioxidant activity} = \frac{[(A_{517\text{control}} - A_{517\text{sample}}) / A_{517\text{control}}] \times 100}{}$$

Nitric oxide scavenging activity

Sodium nitroprusside (5 mmol L⁻¹) in phosphate buffered saline pH 7.4, was mixed with the test sample prepared in methanol and incubated at 25 °C for 30 min. A control without the test compound, but with an equivalent amount of methanol, was taken. After 30 min, 1.5 mL of the incubated solution was removed and diluted with 1.5 mL of Griess reagent (1% sulphanilamide, 2% phosphoric acid and 0.1% N-

1-naphthylethylenediamine dihydrochloride). UV-absorbance of the chromophore formed during diazotization of the nitrite with sulphanilamide and subsequent coupling with N-1-naphthylethylene diamine dihydrochloride was measured at 546 nm and the per centage scavenging activity was measured with reference to the standard.

RESULTS AND DISCUSSION

All the title compounds **4a-l** exhibited characteristic infrared absorption bands for P=N, C=O, -NH and -OH in the regions 1245-1265, 1723-1731 3355-3369 and 3487-3497 cm⁻¹.²¹ The NH protons in thymine gave singlets in the region δ 8.97-9.7.^{22,23} The both NH, NH-CH protons of amino acid ester moieties appeared as a multiplet.²⁴ The P-NH proton resonated as a broad singlet in the region 5.26-5.35 ppm. The H-6' proton signal appeared as a doublet in the region 7.47-7.29 ppm.²⁵ The ¹³C NMR spectral data for **4a**, **4b**, **4c**, **4g**, **4j** are given in the experimental section. The chemical shifts of the carbonyl carbon atom of thymine ring²⁵ appeared at δ 163.8-150.2. The data of other carbon signals are observed in the expected region. The ³¹P NMR chemical shifts appeared in the down field region 6.9-12.9 ppm as expected,¹ due to the deshielding effect of nitrogens and oxygen atoms around P=N system. GC Mass spectra were recorded for a few compounds and they exhibited molecular ion peaks with moderate intensity.



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

The Iminophosphorane derivatives (**4a-l**) exhibited more antioxidant activity when compared to parent compound AZT. Among **4a-l**, **4b**, **4j** and **4k** exhibited very promising antioxidant activity, **4j** exhibited very significant DPPH radical scavenging activity when compared to Vitamin C.

ACKNOWLEDGEMENT

The authors express their grateful thanks to BRNS (DAE) for sanctioning a research project (2007/37/46/ BRNS/ 2916, dated 31-03-2008), Mumbai, India and SAIF, IIT MADRAS (Chennai) for providing NMR, mass spectral data.

REFERENCES

1. Alajarin M, Luna MM, Ortin MM, Andrada PS, Vidal A, Benzylic Newman-Kwart rearrangement of O-azidobenzyl thiocarbamates triggered by phosphines, *Tetrahedron*, 65: 2579–2590, (2009).
2. Gololobov YG, Kasuskhin LF, Recent advances in the Staudinger reaction, *Tetrahedron*, 48: 1353–1406 (1992).
3. Staudinger H, Meyer J, Uber neue organische Phosphorverbindungen III Phosphinmethylenderivate und Phosphinimine, *Helv. Chim. Acta*, 2: 635–646. (1919).
4. Staudinger H, Hauser E, Uber neue organische Phosphorverbindungen IV Phosphinimine, *Helv. Chem. Acta.*, 4: 861–886, (1921).
5. Horner L, Gross A, Die Verwendung der Phosphin-Imine zur Einführung primärer Aminogruppentertiäre Phosphine IV, *Liebigs. Ann. Chem*, 591: 117–134, (1955).
6. Wittig, G, Schwarzenbach, K, Uber methylenierte Metallhalogenide, I, *Liebigs. Ann. Chem*, 650: 1–20, (1961).
7. Molina P, Arques A, Vinader, MV, Iminophosphorane-mediated synthesis of 2H-indazole derivatives: Preparation of 2,3-diamino-2H-indazoles by intramolecular trapping of phosphazides and 1H-1,2,4-triazolo[2,3-b]indazoles by a tandem aza-Wittig/heterocumulene-mediated strategy. *J. Org. Chem*, 55: 4724–4731, (1990).
8. Lin FL, Hoyt HM, Halbeek HV, Bergman RG, Bertozzi CR, Mechanistic Investigation of the Staudinger Ligation, *J. Am. Chem. Soc*, 127: 2686–2695, (2005)
9. Takai Y, Kishimoto A, Inoue M, Nishizuka Y, Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum *J. Biol. Chem*, 252: 7603–7609, (1977).
10. Balzarini J, Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives, *Pharm. World Sci*, 113–126, (1993).
11. Wagner CR, Iyer VV, McIntee EJ, Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides, *Med. Res. Rev*, 20: 417–451, (2000).
12. Wagner CR, Chang S-L, Griesgraber GW, Song H, McIntee, EJ, Zimmerman CL, Antiviral Nucleoside Drug Delivery via Amino acid Phosphoramidates, *Nucleosides Nucleotides Nucleic Acids*, 18: 913–919, (1999).
13. McIntee EJ, Rimmel RP, Schinazi RF, Abraham TW, Wagner CR, Probing the Mechanism of Action and Decomposition of Amino Acid Phosphomonoester Amidates of Antiviral



SYNTHESIS AND BIOLOGICAL ACTIVITY OF DIAZAPHOSPHOLO- IMINOPHOSPHORANE DERIVATIVES OF ZIDOVUDINE (AZT) THROUGH STAUDINGER REACTION

- Nucleoside Prodrugs, *J. Med.Chem*, 40, 3323-3331(1997).
14. Abraham TW, Wagner CR, A Phosphoramidite-Based Synthesis of Phosphoramidate Amino acid diesters of Antiviral Nucleosides Nucleosides Nucleotides *Nucleic Acids*,13: 1891-1903, (1994).
 15. Chang S-L, Griesgraber GW, Southern PJ, Wagner CR, Amino acid Phosphoramidate monoesters of 3'-Azido-3'-deoxythymidine: Relationship between Antiviral potency and Intracellular Metabolism, *J. Med. Chem*, 44: 223-231, (2001).
 16. Iyer VV, Griesgraber GW, Radmer MR, McIntee EJ, Wagner CR, Synthesis, in Vitro Anti-Breast Cancer Activity, and Intracellular Decomposition of Amino Acid Methyl Ester and Alkyl Amide Phosphoramidate Monoesters of 3'-Azido-3'-deoxythymidine (AZT), *J. Med. Chem*, 43: 2266-2274, (2000).
 17. García-de-la-Asunción, Gómez-Cambronero LG, Del Olmo ML, Pallardó, F. V, Sastre, J, Viña J, Vitamins C and E prevent AZT-induced leukopenia and loss of cellularity in bone marrow. *Studies in mice, Free Radical Research*, 41: 330 – 334, (2007).
 18. Armarego, WLF and Perrin DD, Purification of Laboratory Chemicals, fourth ed, Butterworth, Heinemann, Oxford, OX2 8DP, (1997).
 19. Yamaguchi T, Takamura H, Matoba TC, Terao J, HPLC method for evaluation of the free radical-scavenging activity of foods by 1,1-diphenyl-2-picrylhydrazyl, *Biosci Biotechnol Biochem*, 62; 1201–1204. (1998).
 20. Govindarajan R, Rastogi S, Vijayakumar M., Shirwaikar A, Rawat AK, Mehrotra S, Pushpangadan P, Studies on the antioxidant activities of *Desmodium Gangeticum*, *Biol. Pharm. Bull*, 26: 1424–1427, (2003).
 21. Kishore Kumar Reddy KR, Anil Kumar M, Narayana Reddy MV, Devendranath Reddy C, Suresh Reddy C, Chemoselective ring opening of benzoxazaphosphinines, *Tetrahedron Lett*, 49: 6337-6340, (2008).
 22. Shirokova EA, Jasko MV, Khandazhinskaya AL, Ivanov AV, Yanvarev DV, Skoblov YS, Mitkevich VA, Bocharov EV, Pronyaeva TR, Fedjuk NV, Kukhanova MK, Pokrovsky AG, Uncharged AZT and D4T Derivatives of Phosphonoformic and Phosphonoacetic Acids as Anti-HIV Pronucleosides, *J. Med. Chem*, 47: 3606–3614, (2004).
 23. Kim J, Chou TF, Griesgraber GW, Wagner CR, Direct Measurement of Nucleoside Monophosphate Delivery from a Phosphoramidate Pronucleotide by Stable Isotope Labeling and LC–ESI-MS/MS, *Molecular Pharmaceutics*, 1: 102-111, (2004).
 24. Venkatachalam TK, Qazi S, Uckun FM, Synthesis and metabolism of naphthyl substituted phosphoramidate derivatives of stavudine, *Bioorg. Med. Chem*, 14: 5161-5177, (2006).
 25. McGuigan C, Cahard D, Sheeka HM, Clercq ED, Balzarini J, Aryl Phosphoramidate Derivatives of d4T Have Improved Anti-HIV Efficacy in Tissue Culture and May Act by the Generation of a Novel Intracellular Metabolite, *J. Med. Chem*, 39: 1748-1753, (1996)